CA2704430C - Injectable meclizine formulations and methods - Google Patents

Injectable meclizine formulations and methods Download PDF

Info

Publication number
CA2704430C
CA2704430C CA2704430A CA2704430A CA2704430C CA 2704430 C CA2704430 C CA 2704430C CA 2704430 A CA2704430 A CA 2704430A CA 2704430 A CA2704430 A CA 2704430A CA 2704430 C CA2704430 C CA 2704430C
Authority
CA
Canada
Prior art keywords
meclizine
cyclodextrin
pharmaceutically acceptable
chemically modified
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2704430A
Other languages
English (en)
French (fr)
Other versions
CA2704430A1 (en
Inventor
Walker Anderson Long
Edwin Curran Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genebiology Inc
Original Assignee
Genebiology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genebiology Inc filed Critical Genebiology Inc
Publication of CA2704430A1 publication Critical patent/CA2704430A1/en
Application granted granted Critical
Publication of CA2704430C publication Critical patent/CA2704430C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2704430A 2007-10-31 2008-10-31 Injectable meclizine formulations and methods Active CA2704430C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/980,845 US8138192B2 (en) 2007-10-31 2007-10-31 Injectable meclizine formulations and methods
US11/980,845 2007-10-31
PCT/US2008/081973 WO2009059120A2 (en) 2007-10-31 2008-10-31 Injectable meclizine formulations and methods

Publications (2)

Publication Number Publication Date
CA2704430A1 CA2704430A1 (en) 2009-05-07
CA2704430C true CA2704430C (en) 2016-04-05

Family

ID=40583655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704430A Active CA2704430C (en) 2007-10-31 2008-10-31 Injectable meclizine formulations and methods

Country Status (10)

Country Link
US (2) US8138192B2 (enExample)
EP (1) EP2219606B1 (enExample)
JP (1) JP5462797B2 (enExample)
AU (1) AU2008318536B2 (enExample)
CA (1) CA2704430C (enExample)
ES (1) ES2657937T3 (enExample)
NZ (1) NZ584942A (enExample)
PT (1) PT2219606T (enExample)
WO (1) WO2009059120A2 (enExample)
ZA (1) ZA201003524B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2019178536A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Mtor inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60204712A (ja) 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2002032459A2 (en) 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
US20060120967A1 (en) 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils

Also Published As

Publication number Publication date
EP2219606B1 (en) 2017-12-27
ES2657937T3 (es) 2018-03-07
WO2009059120A3 (en) 2009-08-06
CA2704430A1 (en) 2009-05-07
NZ584942A (en) 2012-09-28
US20090111833A1 (en) 2009-04-30
JP2011502169A (ja) 2011-01-20
PT2219606T (pt) 2018-02-02
US8293749B2 (en) 2012-10-23
JP5462797B2 (ja) 2014-04-02
US8138192B2 (en) 2012-03-20
WO2009059120A2 (en) 2009-05-07
EP2219606A4 (en) 2013-03-06
US20120108608A1 (en) 2012-05-03
ZA201003524B (en) 2011-03-30
AU2008318536B2 (en) 2013-09-26
EP2219606A2 (en) 2010-08-25
AU2008318536A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CN102802635B (zh) 麻醉药制剂
EP2785352B1 (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
JP4334229B2 (ja) プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
JP6407221B2 (ja) 抗菌性組成物
KR20160033796A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US20250009885A1 (en) Injectable pharmaceutical formulations of lefamulin
US8293749B2 (en) Injectable meclizine formulations and methods
EP3556349B1 (en) Parenteral liquid preparation comprising carbamate compound
MXPA06008648A (es) Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion.
JP2022513976A (ja) ブラナプラムの経口製剤
US20040072797A1 (en) Storage stable eplerenone formulation
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
HK1064056B (en) An aqueous pharmaceutical preparation of cilostazol for parenteral use
HK1064056A1 (en) An aqueous pharmaceutical preparation of cilostazol for parenteral use
JP2008509141A (ja) 非経口製剤の組織刺激を軽減させる方法及び組成物
HK1252534B (en) Injectable pharmaceutical formulations of lefamulin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131031

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - SMALL

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025